GenEditBio
PrivateLast Round
Strategic
Sep 30, 2024
Total Funding Raised
$10.54M
Momentum
Top 25%
of companies Caplight tracks
Company Overview
GenEditBio operates in Healthcare & Life Sciences and is based in Hong Kong. Its latest recorded funding round was a Strategic round in September 2024.
GenEditBio is a biotechnology company that develops in vivo genome editing-based therapeutic solutions for genetic diseases.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Precision Medicine, Clinical Trials
Business Model
B2B
Customer Profile
Revenue Share, Services & Consulting, Government Contracts
AI Layer
Application
Historical Pricing
Historical view of private secondary pricing and transaction trends.
GenEditBio Comparables
Compare GenEditBio with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Prime Medicine | 75% | |
| Editas Medicine | 75% | |
| Intellia Therapeutics | 75% |
For institutional investors. Book with your work email.
GenEditBio Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Strategic | Sep 30, 2024 | ||||
| Early Funding | Apr 4, 2024 | ||||
| Grant | Mar 1, 2024 | ||||
| Early Funding | May 25, 2022 |
For institutional investors. Book with your work email.
Key People
Founding team and executive leadership
For institutional investors. Book with your work email.
GenEditBio Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| FountainVest Partners | Early Funding |
| Hong Kong Science and Technology Parks Corporation | Early Funding |
| Innovation and Technology Commission | Grant, Early Funding |
| Qiming Venture Partners | Grant, Early Funding |
| Gobi Partners GBA | Strategic |
Market signals
Structured signals derived from secondary market and firmographic data.
- Jul 29, 2026
Monthly visitors increased 35% MoM.
- Apr 16, 2025
Grew 17% QoQ from 18 to 21 employees.
For institutional investors. Book with your work email.
Recent news
Latest coverage and updates
- is_developingNov 1, 2026
GenEditBio Limited is testing GEB-101, a one-shot gene-editing therapy for TGFBI-related corneal dystrophies, in clinical trials in Hong Kong on Nov 1st '26.
For institutional investors. Book with your work email.
GenEditBio Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about GenEditBio's valuation, stock price, and market status.
Is GenEditBio a public or private company?
GenEditBio is a private company.
What is the current stock price of GenEditBio?
GenEditBio is a private company, so its shares have no public market price. Caplight tracks GenEditBio's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is GenEditBio worth (valuation)?
Valuation information for GenEditBio is not publicly available.
Can I buy GenEditBio stock?
GenEditBio shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was GenEditBio's last funding round?
GenEditBio's most recent funding round was Strategic on September 30, 2024.
Who are the main investors in GenEditBio?
Key investors in GenEditBio include Qiming Venture Partners, Gobi Partners GBA.
Will GenEditBio IPO soon?
No public IPO plans have been announced for GenEditBio.
How can I track GenEditBio secondary market activity?
Caplight tracks bids, offers, and trades in GenEditBio's shares on secondary markets.